Showing 6931-6940 of 8607 results for "".
- New Study Investigates Prurigo Nodularis Treatmentshttps://practicaldermatology.com/news/new-study-investigates-prurigo-nodularis-treatments/2457542/Emerging treatments such as neurokinin-1 receptor antagonists show the most promise for prurigo nodularis, according to a review in JAMA Dermatology. Neurokinin-1 receptor is a target of substance P, a medi
- AD, Suicidal Thoughts and Attempts Linkedhttps://practicaldermatology.com/news/ad-suicidal-thoughts-and-attempts-linked/2457543/Patients with eczema may be more likely to have suicidal thoughts and attempts compared to their counterparts without eczema, according to a new study in JAMA Dermatology. Res
- Case Study: Whole Body Cryotherapy Causes Cold Burn Injuryhttps://practicaldermatology.com/news/case-study-whole-body-cryotherapy-causes-cold-burn-injury/2457547/A 71-year-old man experienced a blistering cold burn after receiving a whole-body cryotherapy treatment for back pain and arthritis, according to a
- Asana Biosciences Gets Fast Track Designation from FDA for Dual JAK/SYK Inhibitor for ADhttps://practicaldermatology.com/news/asana-biosciences-gets-fast-track-designation-from-fda-for-dual-jaksyk-inhibitor-for-ad/2457550/The FDA has granted Fast Track designation to Asana BioSciences’ investigational oral Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis. “We are pleased that the FDA has granted Fast Track
- New Xeomin "Later Haters" Campaign Urges Women to “X” Out Judgmenthttps://practicaldermatology.com/news/new-xeomin-later-haters-campaign-aims-to-x-out-judgment/2457487/Merz Americas is launching a new advertising campaign for Xeomin (incobotulinumtoxinA) called “Later Haters,” which urges women to “X out” judgment, stop apologizing for caring about how they look and put an end to f
- Phase 3 Data Positive for Revance's RT002https://practicaldermatology.com/news/phase-3-data-positive-for-revances-rt002/2457489/Long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate to severe glabellar lines in the SAKURA 3 Phase 3 open-label, long-term safety study. Completion of this study paves the way for Revance Therapeutics, Inc. to subm
- New PsA Guidelines from National Psoriasis and Rheumatology Orgs Recommend Treat-to-Target Approachhttps://practicaldermatology.com/news/new-psa-guidelines-from-national-psoriasis-and-rheumatology-orgs-recommend-treat-to-target-approach/2457490/Newly released psoriatic Arthritis (PsA) treatment guidelines from the National Psoriasis Foundation (NPF) and the American College of Rheumatology (ACR) are calling for a treat-to-target approach for all patients with active PsA. What’s more, the guidelines co
- Sinclair Pharma Announces Leadership Changeshttps://practicaldermatology.com/news/sinclair-pharma-announces-leadership-changes/2457491/Sinclair Pharma Limited reported that effective at the end of the year, Doug Abel has resigned his position as Head of North America and President of Silhouette Lift, Inc., to lead a new aesthetic venture and has licensed the US sales and marketing rights to the Refine Support System from Sinclai
- Cosmetic Surgery Forum Kicks Off in Las Vegashttps://practicaldermatology.com/news/cosmetic-surgery-forum-kicks-off-in-las-vegas/2457493/With new and returning faculty, controversial and timely topics, and an all new venue, Cosmetic Surgery Forum (CSF) kicks off its 10th year at the chic Cosmopolitan Hotel. The meeting features 50 sessions and a robust exhibit floor. This year’s Cosmetic Surgery Foru
- Encore Dermatology Announces Phase 2 Safety Data for Impoyzhttps://practicaldermatology.com/news/encore-dermatology-announces-phase-2-safety-data-for-impoyz/2457496/A Phase 2, open-label study published in SKIN The Journal of Cutaneous Medicine, found that subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-treatment clobetasol propionate plasma concentrations versus the subjects treated with Temov